In a report released today, David Westenberg from Piper Sandler reiterated a Buy rating on Natera (NTRA – Research Report), with a price target of $110.00. The company’s shares closed yesterday at $95.55.
Westenberg covers the Healthcare sector, focusing on stocks such as Zoetis, Natera, and Exact Sciences. According to TipRanks, Westenberg has an average return of -1.4% and a 41.98% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Natera with a $108.00 average price target, representing a 13.03% upside. In a report released today, Robert W. Baird also maintained a Buy rating on the stock with a $117.00 price target.
Based on Natera’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $268.31 million and a GAAP net loss of $109.03 million. In comparison, last year the company earned a revenue of $210.64 million and had a GAAP net loss of $121.48 million
Based on the recent corporate insider activity of 131 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NTRA in relation to earlier this year. Most recently, in March 2024, Roelof Botha, a Director at NTRA bought 19,924.00 shares for a total of $840,196.59.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Natera (NTRA) Company Description:
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
Read More on NTRA:
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- TipRanks’ ‘Perfect 10’ List: Analysts See Opportunity in These 2 Top-Scoring Stocks
- Natera announces publication of dd-cfDNA study data
- Natera assumed with a Buy at Craig-Hallum
- Natera announces new data from two studies on Prospera Heart dd-cfDNA test
